Dongsung Pharmaceutical's largest shareholder UAMCO PEF increases stake to 81.98% via convertible bonds under rehabilitation plan, strengthening management stability
Dongsung Pharmaceutical's largest shareholder UAMCO Pharmaceutical Industry No.1 Corporate Financial Stability Private Investment Fund and its special relations acquired convertible bonds worth 50 billion KRW under the rehabilitation plan, increasing their combined stake from 72.64% to 81.98%.
The conversion price of the bonds is 1,000 KRW, potentially issuing up to 50 million new shares upon conversion, creating potential dilution. However, tag-along and drag-along rights agreements among financial and strategic investors aim for long-term management stability.
Under the investor agreement, Taekwang Industry holds a call option on shares held by financial investors and plans to exercise influence for management improvement and corporate growth.
[AI Summary]The majority stake of Dongsung Pharmaceutical increased to 81.98% during the rehabilitation plan execution, significantly strengthening management stability. Although there is potential dilution from convertible bonds, the participation of financial investors and commitment to long-term management support are expected to have a neutral to slightly positive impact on the stock price.
KOSPI Filing Information
Filing: Report on Large Shareholding (General)
Company: Dongsung Pharmaceutical (002210)
Submission: UAMCO Pharmaceutical Industry No.1 Corporate Financial Stability Private Investment Fund